Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response

Journal of Experimental Medicine

Volumn 190, Issue 1, 1999, Pages 125-133

  Chiodoni, Claudia ^a   Paglia, Paola ^a   Stoppacciaro, Antonella ^b   Rodolfo, Monica ^a   Parenza, Mariella ^a   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CD40 ligand; Cross Priming; Dendritic cell; Granulocyte macrophage colony stimulating factor; Tumor antigens

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CELL INFILTRATION; CELL INTERACTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, NEOPLASM; CD40 LIGAND; COLONIC NEOPLASMS; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033526861     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.190.1.125     Document Type: Article

References (44)

1. Steinman, R.M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-296.
2. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature. 392:245-252.
3. Thurnher, M., C. Radmayr, R. Ramoner, S. Ebner, G. Bock, H. Klocker, N. Romani, and G. Bartsch. 1996. Human renal-cell carcinoma tissue contains dendritic cells. Int. J. Cancer. 67:1-7.
4. Becker, Y. 1992. Anticancer role of dendritic cells (DC) in human and experimental cancers - a review. Anticancer Res. 12:511-520.
5. Huang, A.Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC-I-restricted tumor antigens. Science. 264:961-965.
6. Dieu, M.C., B. Vanbervliet, A. Vicari, J.M. Bridon, E. Oldham, S. Ait-Yahia, F. Briere, A. Zlotnik, S. Lebecque, and C: Caux. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188:373-386.
7. Sallusto, F., and A. Lanzavecchia. 1999. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J. Exp. Med. 189:611-614.
8. Albert, M.L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class-I restricted CTLs. Nature. 392:86-89.
9. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1359-1368.
10. Albert, M.L., and N. Bhardwaj. 1998. Resurrecting the dead: DCs cross-present antigen derived from apoptotic cells on MHC I. The Immunologist. 6:194-198.
11. Melcher, A., S. Todryk, N. Hardwick, M. Ford, M. Jacobson, and R.G. Vile. 1998. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 4:581-587.
12. Srivastava, P.K., A. Menoret, S. Basu, R.J. Binder, and K.L. McQuade. 1998. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity. 8:657-665.
13. Stoppacciaro, A., P. Paglia, L. Lombardi, G. Parmiani, C. Baroni, and M.P. Colombo. 1997. Genetic modification of a carcinoma with IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur. J. Immunol. 27:1570-1575.
14. Nathan, C., and M. Sporn. 1991. Cytokines in context. J. Cell Biol. 113:981-986.
15. Grabbe, S., S. Bruvers, R.L. Gallo, T.L. Knisely, R. Nazareno, and R.D. Granstein. 1991. Tumor antigen presentation by murine epidermal cells. J. Immunol. 146:3656-3661.
16. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 176:519-529.
17. Grewal, I.S., and R.A. Flavell. 1998. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:111-135.
18. Banchereau, J., F. Bazan, D. Blanchard, F. Briere, J.P. Galizzi, C. van Kooten, Y.J. Liu, F. Rousset, and S. Saeland. 1994. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12:881-922.
19. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747-752.
20. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741-746.
21. van Kooten, C., and J. Banchereau. 1997. Function of CD40 on B cells, dendritic cells and other cells, Curr. Opin. Immunol. 9:330-337.
22. Miller, A.D., and G.J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. Biotechniques. 7:980-990.
23. Stoppacciaro, A., C. Melani, M. Parenza, A. Mastracchio, C. Bassi, C. Baroni, G. Parmiani, and M.P. Colombo. 1993. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon γ. J. Exp. Med. 178:151-161.
24. Huang, A.Y., P.H. Gulden, A.S. Woods, M.C. Thomas, C.D. Tong, W. Wang, V.H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA. 93:9730-9735.
25. Rodolfo, M., C. Bassi, C. Salvi, and G. Parmiani. 1991. Therapeutic use of a long-term cytotoxic T cell line recognizing a tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours. Cancer Immunol. Immunother. 34:53-62.
26. Rodolfo, M., C. Castelli, C. Bassi, P. Accornero, M. Sensi, and G. Parmiani. 1994. Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors. Int. J. Cancer. 57:440-447.
27. Sijts, A.J., F. Ossendorp, E.A. Mengede, P.J. van den Elsen, and C.J. Melief. 1994. Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class-I binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes. J. Immunol. 152:106-116.
28. Jahner, D., and R. Jaenisch. 1985. Chromosomal position and specific demethylation in enhancer sequences of germ line-transmitted retroviral genomes during mouse development. Mol. Cell. Biol. 5:2212-2220.
29. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R.C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting tumor immunity. Proc. Natl. Acad. Sci. USA. 90:3539-3543.
30. Armstrong, C.A., R. Botella, T.H. Galloway, N. Murray, J.M. Kramp, I.S. Songs, and J.C. Ansel. 1996. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res. 56:2191-2198.
31. Allione, A., M. Consalvo, P. Nanni, P.L. Lollini, F. Cavallo, M. Giovarelli, M. Forni, A. Gulino, M.P. Colombo, P. Dellabona, et al. 1994. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res. 54:6022-6026.
32. Dilloo, D., K. Bacon, W. Holden, W. Zhong, S. Burdach, A. Zlotnik, and M. Brenner. 1996. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat. Med. 2:1090-1095.
33. Levitsky, H.I. 1997. The best cytokine for the job. Nat. Med. 3:126.
34. + T cells and granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 188:133-143.
35. Grossmann, M.E., M.P. Brown, and M.K. Brenner. 1997. Antitumor responses induced by transgenic expression of CD40 ligand. Hum. Gene Ther. 8:1935-1943.
36. Nakajima, A., T. Kodama, S. Morimoto, M. Azuma, K. Takeda, H. Oshima, S. Yoshino, H. Yagita, and K. Okumura. 1998. Antitumor effect of CD40 ligand. Elicitation of local and systemic antitumor responses by IL-12 and B7. J. Immunol. 161:1901-1907.
37. Inaba, K., S. Turley, F. Yamaide, T. Iyoda, K. Mahnke, M. Inaba, M. Pack, M. Subklewe, B. Sauter, D. Sheff, et al. 1998. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med. 188:2163-2173.
38. + T cell help. J. Exp. Med. 186:65-70.
39. Bennett, S.R., F.R. Carbone, F. Karamalis, R.A. Flavell, J.F. Miller, and W.R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 393:478-480.
40. Schoenberger, S.P., R.E. Toes, E.I. van der Voort, R. Offringa, and C.J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393:480-483.
41. Cayeux, S., G. Richter, C. Becker, A. Pezzutto, B. Dorken, and T. Blankenstein. 1999. Direct and indirect T cell priming by dendritic cell vaccines. Eur. J. Immunol. 29:225-234.
42. Ridge, J.P., F. Di Rosa, and P.A. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 393:474-478.
43. Paglia, P., C. Chiodoni, M. Rodolfo, and M.P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317-322.
44. Kurts, C., W.R. Heath, F.R. Carbone, J. Allison, J.F. Miller, and H. Kosaka. 1996. Constitutive class I-restricted exogenous presentation of self antigen in vivo. J. Exp. Med. 184: 923-930.